Initiator Pharma: Financial calendar for 2022

Regulatory

Initiator Pharma A/S ("Initiator" or the "Company") announces that the board of directors expects to publish financial reports according to the following schedule:

Year-end report 2021 (Q4) 18 February 2022
Interim Q1 2022 report 6 May 2022
Annual General Meeting 2022 20 May 2022
Interim report 1st half 2022 19 August 2022
Interim Q3 2022 report 4 November 2022
Year-end report 2022 (Q4) 17 February 2023

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: [email protected]

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of three clinical programs – the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition. 
 
Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB, with email address [email protected] and phone number +46 8 121 576 90, is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

Initiator Pharma: Financial calendar for 2022

Documents